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Arrhythmogenic right ventricular cardiomyopathy (ARVC), an
inherited heart muscle disease, is associated with a high risk of
arrhythmias and sudden cardiac death [1]. It is characterized
primarily by ﬁbrofatty replacement of the right ventricular myo-
cardium, which is often accompanied by subsequent progression
to the left ventricle [2,3]. ARVC is genetically determined by
autosomal dominant inheritance, although recessive subtypes
have been observed [4]. Mutations in genes coding for desmoso-
mal proteins, including desmoplakin, plakoglobin, plakophilin 2
(PKP 2), desmoglein 2, and desmocollin 2, have been identiﬁed in a
signiﬁcant number of patients [5]. The clinical presentation of
ARVC varies widely; diagnosis is often complex and involves
structural, histological, electrocardiographic, arrhythmic, and
genetic tests for the disease [6]. Diagnosis is particularly difﬁcult
during the early phases of the disease when structural changes are
not well-developed, leading to under-diagnosis. However, in this
usually asymptomatic phase, some individuals may be at risk of
sudden cardiac death. As such, it is important to increase the
understanding of this complex condition through more patient-
centered approaches, which may help with both diagnosis and
management.
Animal models have provided insight into the underlying
mechanisms and pathophysiology of ARVC [4]. However, differ-
ences in functional and conduction properties between animal and
human cardiomyocytes limit the general applicability of these
results. The advent of induced pluripotent stem cell (iPSC) tech-
nology has greatly changed the landscape [7]. iPSCs are pluripo-
tent stem cells derived from somatic cells through the induction of
gene expression; these cells can then be reprogrammed to
differentiate into other mature cell lines. In 2006, Yamanaka
et al. pioneered this technology in mice followed by in human
cells [7]. Since then, human iPSCs have been shown to be capable
of differentiating into cardiomyocytes with cardiac-speciﬁc mole-
cular, structural, and functional properties, indicating their great
potential for the development of in vitro models of genetic
cardiomyopathies [8].
Models patient-speciﬁc iPSCs have been used to study various
inherited cardiac disorders. iPSC models were developed for the
examination of long QT syndrome and have shed light on the
mechanism of arrhythmogenicity in these cells (such as early-after
depolarizations and triggered arrhythmias) and were used to
evaluate the effectiveness of current and new agents to treat the
disease phenotype [9]. For hypertrophic cardiomyopathy, iPSC
models have increased the understanding of the molecular path-
ways of hypertrophy and arrhythmogenesis involved in abnormal
calcium regulation and homeostasis within the cardiac sacromere
[10]. Similar models have shed light on the pathogenesis and
treatment of other cardiac disorders such as familial dilated
cardiomyopathy [11] and catecholaminergic polymorphic ventri-
cular tachycardia [12].
Thus, using patient-speciﬁc iPSCs models for studying ARVC has
immense potential beneﬁts, allowing for an increased understanding
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of the pathogenesis, risk stratiﬁcation, and diagnosis of ARVC
patients, as well as exploration of potential therapeutic options.
However, stem cell models must accurately reﬂect the mutations and
characteristics of the disease. In a histopathological study involving
myocardial biopsy samples acquired from patients with ARVC,
Asimaki et al. found a marked reduction in immunoreactive signals
for plakoglobin, but normal levels of the non-desmosomal adhesion
molecule N-cadherin in ARVC patients [13]. The authors suggested
that this is a potentially useful new diagnostic test with a sensitivity
and speciﬁcity of 91% and 82%, respectively. The test is limited
because it requires myocardial biopsy, an invasive procedure with
associated risks. Therefore, a less invasive but accurate and speciﬁc
test may be more acceptable to patients and have a greater clinical
impact.
The ﬁrst in vitro cellular model of ARVC by using patient-speciﬁc
iPSC-derived cardiomyocytes was described by Ma et al. in 2012.
They produced functional iPSC-derived cardiomyocytes by retro-
viral reprogramming of dermal ﬁbroblasts taken from a male with
clinical features of ARVC harboring a PKP2 gene mutation [14]. The
results provided novel insights into the disease. First, reduced gene
expression of desmosomal proteins (PKP2 and plakoglobin) was
observed compared to controls, with lower immunoﬂuorescence
signals for these proteins at the cell periphery. Second, after
exposure of cardiomyocytes to adipogenic differentiation medium
for 2 weeks, the investigators found greater amounts of lipids in
ARVC cells compared to in control cells. This was conﬁrmed by
both Oil Red O staining for intracellular lipid droplets and qualita-
tively based on transmission electron microscopy. These ﬁndings
indicate the abnormal trafﬁcking or expression of desmosomal
proteins in mutant cells and indicate an increased adipogenic
potential in mutant cells, which may predispose patients to ﬁbro-
fatty changes observed in ARVC.
Two other groups subsequently published further data on
in vitro iPSCs models of ARVC that have improved our under-
standing of this disease. Kim et al. developed iPSC models using
episomal methods from 2 ARVC patients, as well as with PKP2
mutations [15]. Detailed electrophysiological characterization of
mutant and control cardiomyocytes and alteration of the external
pathogenic conditions using hormones and small molecules
resulted in accelerated pathogenesis of the adult-onset phenotype.
Important changes in intracellular calcium handling in mutant
iPSC-derived cardiomyocytes were also observed, as well as the
induction of adult-like metabolism and abnormal peroxisome
proliferator-activated receptor gamma (PPAR-γ) activation, which
were important in the pathogenesis of ARVC. To explain the
predominant pathological characteristics of ARVC in the right
ventricle, the investigators increased the number of Islet
1-positive cardiac progenitor cells by approximately 4-fold in
mutant PKP2 iPSCs, simulating natural right ventricle formation
of the secondary heart ﬁeld. Caspi et al. also modeled ARVC from
2 patients with PKP2 mutations [16]. Similarly, they found reduced
PKP2 and plakoglobin expression as well as increased adipogeni-
city in ARVC cells, along with upregulation of PPAR-γ. Additionally,
they found that the degree of adipogenicity was closely related to
the extent of desmosomal abnormalities, suggesting “crosstalk”
between desmosomal destruction and adipogenesis, and that
ARVC cardiomyocytes were at an increased risk of apoptosis.
Despite important advances in our understanding of inherited
cardiovascular diseases based on patient-speciﬁc iPSC-models, the
technology remains challenging and shows some limitations [17].
The currently used models predominantly involve single cells; thus,
it is unclear whether these cells replicate more complex processes
involving synchronized groups of beating cardiomyocytes at the
tissue or organ level, rather than just at the cardiomyocyte level.
The currently used models do not fully assess the pathophysiolo-
gical changes that may affect cell–cell interactions, which may play
a role in diseases such as ARVC. Models must be reﬁned to include
layers of synchronized functional cardiomyocytes and explore the
intercellular interactions in mutant and control cells. Furthermore,
ARVC and other cardiomyopathies such as dilated cardiomyopathy
are predominantly adult-onset diseases. Because iPSC-derived car-
diomyocytes are relatively immature cells, it is unclear whether the
changes observed in these cells truly reﬂect all pathophysiological
changes in adult cells. Several novel methods have recently been
reported, and they may improve the maturation of iPSC-derived
cardiomyocytes and thus help overcome this limitation. These
techniques include prolonged in vitro cell culture [18,19], bio-
mimetic culturing using forced expression of Kir2.1 [20], and using
a novel platform (consisting of biowires submitted to electrical
stimulation) which combines 3-dimensional cell cultivation with
electrical stimulation [21]. Finally, although ARVC iPSC-models
described to date show adipogenic changes in mutant cells
in vitro, the precise mechanisms and external factors responsible
for these changes in ARVC patients in vivo remain unknown.
Despite these challenges, the ability to use patient-speciﬁc
iPSCs to model ARVC was shown to be useful in studies of the
disease, providing vital knowledge regarding the pathogenesis of
AVRC as well as providing opportunities to design and test novel
diagnostic strategies and therapeutics. ARVC-iPSC models
described to date involved patients with PKP2 gene mutations.
Future studies examining ARVC patients with different mutations
are necessary to determine whether there is a common patho-
physiological abnormality in AVRC or varying mechanisms
depending on the speciﬁc mutation. More detailed electrophysio-
logical and functional studies are needed to elucidate the mechan-
isms underlying life-threatening cardiac arrhythmias observed in
patients with ARVC.
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